Protocol for Desensitization to Atezolizumab and Bevacizumab After Severe Anaphylaxis in the Treatment of Lung Adenocarcinoma

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of investigational allergology & clinical immunology 2021-06, Vol.31 (3), p.265-267
Hauptverfasser:	Gonzalez-Diaz, S N, Villarreal-Gonzalez, R V, De Lira-Quezada, C E, Rocha-Silva, G K, Oyervides-Juarez, V M, Vidal-Gutierrez, O
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - complications Adenocarcinoma - drug therapy Anaphylaxis - etiology Anaphylaxis - prevention & control Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Bevacizumab - adverse effects Bevacizumab - therapeutic use Desensitization, Immunologic - methods Drug Hypersensitivity - complications Drug Hypersensitivity - therapy Drug-Related Side Effects and Adverse Reactions - prevention & control Humans Lung Neoplasms - complications Lung Neoplasms - drug therapy Male Middle Aged Severity of Illness Index Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!